In his latest blog post, ACSH s Dr. Josh Bloom takes a look at what he calls the two faces of cancer that is, the discovery of a few amazing breakthroughs in the treatment of certain cancers, compared to the disappointing reality that the current generation of super drugs has not lived up to expectations. Tumor heterogeneity the wide range of genetic variations among cancer cells is turning out to be a bigger hurdle than expected. At Medical Progress Today, read Dr.
In his latest blog post, ACSH s Dr. Josh Bloom takes a look at what he calls the two faces of cancer that is, the discovery of a few amazing breakthroughs in the treatment of certain cancers, compared to the disappointing reality that the current generation of super drugs has not lived up to expectations. Tumor heterogeneity the wide range of genetic variations among cancer cells is turning out to be a bigger hurdle than expected. At Medical Progress Today, read Dr. Bloom s discussion of the problem.
